Why the study?
Does intravenous liposomal clodronate accelerate the development of cardiomyopathy in heart failure-prone hypertensive Ren-2 rats?
Does intravenous liposomal clodronate accelerate the development of cardiomyopathy in heart failure-prone hypertensive Ren-2 rats?
Macrophage depletion accelerates myocardial dysfunction and cardiomyopathy development in a hypertensive rat model, suggesting macrophages play a protective role in chronic cardiac remodeling.
Macrophage depletion may accelerate cardiomyopathy in hypertensive models; leaves open their protective role in human remodeling.
Inflammation contributes to the process of ventricular remodeling after acute myocardial injury. To investigate the role of macrophages in the chronic process of cardiac remodeling, they were selectively depleted by intravenous administration of liposomal clodronate in heart failure-prone hypertensive Ren-2 rats from the age of 7 until 13 weeks. Plain liposomes were used for comparison. Liposomal clodronate treatment reduced the number of blood monocytes and decreased the number of macrophages in the myocardium. Compared to plain liposomes, liposomal clodronate treatment rapidly worsened left ventricular ejection function in hypertensive rats. Liposomal clodronate- treated Ren-2 rat hearts showed areas of myocyte loss with abundant inflammatory cell infiltration, predominantly comprising CD4 positive T lymphocytes. The current study showed that lack of macrophages was associated with earlier development of myocardial dysfunction in hypertensive rats. Modulation of macrophage function may be of value in the evolution of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Zandbergen et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: